From acute injury to Functional Recovery​

A new approach to Spinal Cord Injury (SCI) treatment, based on
siRNA-PTEN Loaded exosome administration. Exo-PTEN Holds a broad potential for variety of Central Nerve System (CNS) indications and may offer a revolutionary non-invasive "of the shelf" product


NurExone Biologic Ltd is developing a revolutionary biological Exosome based technology drug platform to treat damage in the Central Nerve System (CNS).

The breakthrough Exosome based technology was proven in animal studies, to have the potential to treat Spinal Cord Injuries (SCI).

The Company’s research and development activities are based in Israel.

NurExone has been granted an exclusive worldwide license to develop and commercialize the technology by the Technion, Haifa and Tel Aviv University, both located in Israel.

intranasal exosome administration

Neuronal damage in general and SCI in particular involves a long and complex cascade of secondary events following the injury itself. The complexity of the cascade can affect the efficiency of the suggested treatments and there remains an unmet need for development of additional safe, efficient and convenient methods for treating SCI.

The new approach to SCI treatment is based on the view that intranasal exosome administration has broad potential and offers an alternative to different potential treatments, including cell transplantation, in treating SCI.

Extensive research, conducted at Prof. Shulamit Levenberg’s lab at the Technion in collaboration with Prof. Danny Offen from Tel Aviv University, tested a novel proprietary treatment using intranasal administration of Exosomes driven from mesenchymal stem cells loaded with siRNA PTEN targeting spinal cord lesion in rats with complete SCI. The results were stunning , showing neuron growth and significant functional recovery.


NurExone Biologic has a multi-disciplinary management and scientific advisory board

Dr. Lior Shaltiel – An entrepreneur and awarded scientist with extensive multidisciplinary international experience, specializing in chemical engineering, electrophysiology, pharmacology and drug delivery systems.

Ron Mayron – Former CEO of Teva Israel, one of the largest generic pharmaceutical companies in the world.

Yoram Drucker – Founder of two Nasdaq traded companies – Pluristem Therapeutics (NASDAQ: PSTI ) & Brainstorm Cell Therapeuitics (NASDAQ:BCLI), both working with stem cells.

Prof. Shulamit Levenberg – Conducts interdisciplinary research on stem cells and tissue engineering. She is the Dean of the Biomedical Engineering Department, Technion.

Prof. Danny Ofen – Concentrates on the processes of cell death in neurodegenerative diseases, specifically in Parkinson’s and ALS. He is the Head of the Neurosciences Lab at Felsenstein Medical Research Center, Tel Aviv University.

Dr. Maya Halperin – Medical doctor with nearly 20 years of experience in the pharmaceutical industry. Former Medical Director at Teva, in charge of Regulatory affairs, Clinical Trials and Medical Marketing,